Author

Systemic treatment

Systemic treatment regimen

Surgical technique and additional treatments

Balke et al. [19]

Perioperative or Postoperative or Non-operative IV or PO Bisphosphonates

Either perioperative or postoperative or non-operative IV zoledronic acid 4 mg for 1 - 6 doses over variable time course (n = 18) or postoperative IV alendronate 70 mg weekly for 24 - 32 months (n = 2) or postoperative or non-operative PO clodronate 2 × 800 mg daily for 12 - 60 months (n = 4) or postoperative IV pamidronate 90 mg monthly for unknown course (n = 1)

Non surgical cases = 3 of 25 (12%)

In some cases of progressive disease were treated with preoperative selective artery embolization , adjuvant radiotherapy, or other systemic chemotherapy.

Chawla et al. [18]

Post-operative or Non-operative RANK Ligand Antibody

Cohorts 1 and 2^*—Subcutaneous denosumab 120 mg every 4 weeks (plus additional doses on day 8 and 15 in first cycle only). Eventual surgical patients in cohort 2 received 6 doses of denosumab postoperatively (n = 26). The median number of doses across all cohorts was 13.0 (7.0 - 20.0). Cohort 3^*—Continued previous regimen (denosumab 120mg every 4 weeks).

Past treatments included surgery, radiation, chemotherapy or immunotherapy, IV or oral bisphosphonates.